Эффекты фенофибрата у пациентов с сахарным диабетом 2 типа, осложненным диабетической нейропатией

Diabetic neuropathy is a severe complication of diabetes mellitus (DM) that considerably worsens the patients quality of life and reduces life expectancy. The FIELD study for the first time demonstrated the ability of fenofibrate to prevent macroand microvacular complications in patients with DM2 regardless of glycated hemoglobin level and dyslipidemia at the early stage of the disease. Neuropathy being a manifestation of microangiopathy, it suggests the possibility to treat this disorder with fenofibrate. Aim. To study effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy. Materials and methods. The present study included 73 patients with DM2 randomized into 2 groups to receive standard therapy (antihypertensive and glucose control, statins) or fenofibrate (Tricor 145 mg, Solvay Pharma) in addition to the standard treatment. Results. Positive effect of fenofibrate on autonomous and peripheral neuropathy was apparent within 6 months after the onset of therapy when the sought parameters of AP, glycemia, and lipid spectrum were achieved. Fenofibrate improved cardiovascular function, reduced cardiac rhythm variability QT length and dispersion, pain and paresthesia thereby enhancing quality of life and preventing cardiovascular catastrophes including death. Conclusion. It is concluded that supplementation of standard therapy of DM with fenofibrate is both safe and pathogenetically sound.